Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.
Bocchia M, Carella AM, Mulè A, Rizzo L, Turrini M, Abbenante MC, Cairoli R, Calafiore V, Defina M, Gardellini A, Luzi G, Patti C, Pinazzi MB, Riva M, Rossi G, Sammartano V, Rigacci L. Bocchia M, et al. Among authors: rossi g. Pharmgenomics Pers Med. 2022 Apr 22;15:393-407. doi: 10.2147/PGPM.S346688. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 35496349 Free PMC article.
Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G, Carella AM, Minervini MM, Savino L, Fontana A, Pellegrini F, Greco MM, Merla E, Quarta G, Loseto G, Capalbo S, Palumbo G, Cascavilla N. Rossi G, et al. Leuk Lymphoma. 2013 Dec;54(12):2660-6. doi: 10.3109/10428194.2013.789508. Epub 2013 May 15. Leuk Lymphoma. 2013. PMID: 23547840
Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.
Rossi G, Carella AM, Minervini MM, di Nardo F, Waure Cd, Greco MM, Merla E, Cillis GP, Di Renzo N, Melpignano A, Capalbo S, Palumbo G, Pisapia G, Cascavilla N. Rossi G, et al. Leuk Res. 2015 Feb;39(2):138-43. doi: 10.1016/j.leukres.2014.11.011. Epub 2014 Nov 29. Leuk Res. 2015. PMID: 25498507
Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G, Falcone AP, Minervini MM, De Cillis GP, De Waure C, Sisti LG, Giambra V, Valente D, Chiello V, Scalzulli PR, Carella AM, Cascavilla N. Rossi G, et al. Cytometry B Clin Cytom. 2019 May;96(3):195-200. doi: 10.1002/cyto.b.21755. Epub 2018 Dec 13. Cytometry B Clin Cytom. 2019. PMID: 30549231 Free article.
Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
Rossi G, Giambra V, Minervini MM, De Waure C, Mancinelli S, Ciavarella M, Sinisi NP, Scalzulli PR, Carella AM, Cascavilla N. Rossi G, et al. Cytometry B Clin Cytom. 2020 May;98(3):216-225. doi: 10.1002/cyto.b.21855. Epub 2019 Nov 7. Cytometry B Clin Cytom. 2020. PMID: 31697027 Free article.
Log reduction of leukemic cells and minimal residual disease by flow cytometry represent effective predictors of clinical outcome in elderly patients with acute myeloid leukemia.
Rossi G, Giambra V, de Waure C, Giacchetta I, Minervini MM, Abbenante MC, Spadano R, La Torre A, Scalzulli PR, Cascavilla N. Rossi G, et al. Cytometry B Clin Cytom. 2022 Jan;102(1):26-33. doi: 10.1002/cyto.b.22010. Epub 2021 May 13. Cytometry B Clin Cytom. 2022. PMID: 33983682 Free article.
Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia.
Panelli P, De Santis E, Colucci M, Tamiro F, Sansico F, Miroballo M, Murgo E, Padovano C, Gusscott S, Ciavarella M, Chavez EA, Bianchi F, Rossi G, Carella AM, Steidl C, Weng AP, Giambra V. Panelli P, et al. Among authors: rossi g. Blood. 2023 Mar 30;141(13):1597-1609. doi: 10.1182/blood.2022017079. Blood. 2023. PMID: 36315912 Free PMC article.
Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network.
Dargenio M, Tarantini G, Cascavilla N, Pavone E, Musto P, Mazza P, Melillo L, Pastore D, Guarini A, Buquicchio C, Fina MP, Federico V, Santeramo TM, Urbano MA, Leo M, Carluccio V, Carluccio P, Delia M, Carlino D, Vergine C, Gagliardi VP, Greco G, Sibilla S, Abbenante M, Rossi G, Spinosa G, Mazzone A, Aprile L, de Fazio V, Pasciolla C, Specchia G, Di Renzo N. Dargenio M, et al. Among authors: rossi g. Cancers (Basel). 2022 Feb 6;14(3):826. doi: 10.3390/cancers14030826. Cancers (Basel). 2022. PMID: 35159092 Free PMC article.
Combination treatment of flag with non-pegylated liposomal doxorubicin (MYOCET(TM)) in elderly patients with acute myeloid leukemia: a single center experience.
Melillo L, Valente D, D'Arena G, Dell'Olio M, Falcone A, Minervini MM, Nobile M, Rossi G, Sanpaolo G, Scalzulli PR, Cascavilla N. Melillo L, et al. Among authors: rossi g. Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):703-9. doi: 10.1177/039463201102400316. Int J Immunopathol Pharmacol. 2011. PMID: 21978702 Free article.
5,823 results